TY  - JOUR
AU  - Romero, Miguel E. jimenez
AU  - Gallego, Maria Camacho
AU  - Serrato, Jose c. navarro
AU  - Sanchez Hurtado, Miguel A.
AU  - Santotoribio, Jose D.
PY  - 2021
DO  - 10.21873/anticanres.15192
SN  - 0250-7005
UR  - https://hdl.handle.net/10668/25155
T2  - Anticancer research
AB  - Background/Aim: The aim of the study was to evaluate the combined treatment with abiraterone acetate and prednisone (AA+P) in patients with castration resistant prostate cancer (mCPRC), and to identify the survival prognostic factors. Patients and...
LA  - en
PB  - Int inst anticancer research
KW  - Prostate cancer
KW  - castration-resistant
KW  - abiraterone acetate
KW  - prednisone
KW  - chemo-naive
KW  - survival
KW  - prognostic models
KW  - Clinical-outcomes
KW  - Plus prednisone
KW  - Antigen
KW  - Men
KW  - Model
KW  - Enzalutamide
KW  - Cou-aa-302
KW  - Diagnosis
TI  - Treatment of Metastatic Castration-resistant Prostate Cancer Patients With Abiraterone Acetate and Prednisone and Corresponding Survival Prognostic Factors
TY  - research article
VL  - 41
ER  -